Evaluating Mesenchymal Stem Cell Supernatant for Healing Mucosal Injuries in Patients After Hematopoietic Stem Cell Transplantation

What this Trial Is About

Researchers are evaluating the effects of mesenchymal stem cell MSC culture supernatant on preventing and treating mucosal injuries in patients undergoing hematopoietic stem cell transplantation HSCT. HSCT is a treatment for blood cancers and disorders but often causes severe damage to the mouth lining, skin, and bladder due to high-dose chemotherapy and radiation. This study aims to see if MSC supernatant, which contains healing substances from stem cells, can help repair these injuries and improve recovery without risks related to live cell therapies. Participants will be randomly assigned to two groups one receives standard care, including oral rinses and pain relief, while the other receives MSC supernatant in addition to standard care. The MSC supernatant will be used as a mouthwash for oral injuries, applied topically for skin injuries, and used for bladder irrigation in bladder injuries. The study will monitor healing progress, safety, and side effects over the course of treatment. During the study, participants will have regular weekly assessments and monthly follow-ups to monitor healing using standardized injury scales and pain scores. Laboratory tests and vital signs will be checked to ensure safety. Researchers will also track infection rates, hospital stay lengths, and quality of life. The trial lasts from October 2020 to September 2025, with 120 patients expected to participate and be followed throughout the study.

Effects of Mesenchymal Stem Cell Supernatant on Prevention and Treatment of Skin/Mucosal Injury in Hematology Patients